Sangamo Therapeutics: Preliminary Data Shows Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients with Fabry Disease

Sangamo Therapeutics Preliminary Results Evaluating Isaralgagene Civaparvovec for Fabry Disease
Sangamo Therapeutics (SGMO) announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920 - a wholly owned gene therapy product candidate, for Fabry disease.

As of the September 17, 2021 cutoff date, results from the four patients treated in the first two dose cohorts (0.5e13 vg . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.